Liver Dysfunction Assessed by Albumin – Bilirubin (ALBI) Score is Associated with Disturbed Cholesterol Profiles and Reduced Survival in Patients with Chronic Limb-Threatening Ischemia Authors: Kentaro Inoue, Shinichiro Yoshino, Yutaka Matsubara, Tadashi Furuyama, Toshihiro Onohara Published: 2026 ABSTRACT Aims: Liver dysfunction may affect chronic limb-threatening ischemia (CLTI) outcomes, but its impact on survival and lipid profiles is unclear. To assess the association of liver dysfunction using the Albumin–Bilirubin (ALBI) score, with survival, liver fibrosis, and cholesterol in CLTI patients. Methods: We retrospectively analyzed single-center data of CLTI patients with below-knee lesions between 2008–2018. ALBI scores were calculated from serum albumin and total bilirubin. Optimal cutoff for 3-year overall survival (OS) was determined by receiver operating characteristic (ROC) analysis, dividing patients into high and low ALBI groups. Patient characteristics, cholesterol, and liver fibrosis (FIB-4 index) were compared, with primary endpoint being 3-year OS. Results: Among 263 patients, high ALBI patients (≥ -2.36,n = 135) were older (80 vs. 72 years), included fewer males (55% vs. 71%), had higher prevalence of bed-ridden status (44% vs. 2%) and heart failure (25% vs. 8%; allP<0.01). They had higher FIB-4 index (2.49 vs. 1.76), lower total cholesterol (147 vs. 173 mg/dL), HDL-C (43 vs. 56 mg/dL), LDL-C (83 vs. 108 mg/dL), and higher LDL-C/HDL-C ratio (2.57 vs. 2.20;P<0.01). Three-year OS was lower in high ALBI group (36% vs. 57%;P<0.01) and remained lower after propensity matching (43% vs. 55%;P = 0.04). Multivariate analysis identified low body mass index (BMI), heart failure, high ALBI score and high FIB-4 index (≥ 1.3) and low LDL-C (<100 mg/dL) as predictors of poor OS. Conclusions: High ALBI scores in CLTI patients links to liver fibrosis, disturbed lipid profiles, and reduced survival. Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease—has become a major cause of liver disease 1) . A meta-analysis estimated the global prevalence of MASLD at 38%, representing a 50% increase over the past 20 years 2) . This trend is particularly relevant for cardiologists, as MASLD/NAFLD shares many risk factors with atherosclerosis, including metabolic syndrome, type 2 diabetes mellitus, and hypertension 3) , and is associated with an increased risk of cardiovascular disease 4 - 6) . Peripheral artery disease (PAD) is one of the major atherosclerotic conditions, and chronic limb-threatening ischemia (CLTI) represents its advanced stage, characterized by ischemic rest pain, tissue loss, or gangrene. Despite the shared risk factors between MASLD and atherosclerosis, the influence of liver function on PAD and CLTI remains poorly understood. This knowledge gap may partly stem from the “silent” nature of liver disease, as liver dysfunction often progresses without noticeable symptoms until advanced stages, and liver function assessment has not been routinely prioritized in PAD patients. Concurrently, serological systems for evaluating liver function and fibrosis, such as the Albumin–Bilirubin (ALBI) score and fibrosis-4 (FIB-4) index, have been established 7) . The ALBI score is an objective, statistically derived measure based solely on serum albumin and total bilirubin levels. Beyond liver disease, recent studies have highlighted the relevance of ALBI scores for cardiovascular outcomes, including heart failure. The FIB-4 index, originally developed to assess liver fibrosis, has also been associated with atherosclerosis and cardiovascular risk 8 - 11) . One potential mechanism by which liver dysfunction may exacerbate atherosclerosis is through abnormal cholesterol metabolism. The liver plays a central role in lipoprotein production and high-density lipoprotein cholesterol (HDL-C) efflux, both of which are strongly linked to atherogenesis 12 - 14) . In this study, we investigated the impact of liver dysfunction, defined by ALBI score, on survival in CLTI patients, with particular focus on their cholesterol profiles. Materials and Methods Study Design and Ethics Approval This retrospective study assessed patient outcomes using data collected during routine diagnosis and treatment. The study protocol was approved by the institutional ethics committee of Kyushu Medical Center and conducted in accordance with the Declaration of Helsinki (Approval No. 23C120). Informed consent was waived due to the retrospective design; study information was disclosed to patients via hospital bulletins as an alternative to written consent. Patients We retrospectively reviewed patients who presented to the Department of Vascular Surgery at Kyushu Medical Center with Rutherford stage 5 or 6 CLTI and below-knee lesions between January 2008 and December 2018. A total of 263 patients were included. Data were obtained from medical, operative, and radiological records for analysis. Patient Baseline Characteristics Patient baseline characteristics, including age, sex, body mass index (BMI), smoking history, ambulatory status, and comorbidities, were recorded. Laboratory data at admission were also collected. Triglycerides, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), HDL-C, remnant-like particle cholesterol (RLP-C) were measured in 244, 244, 241, 243, and 150 patients, respectively. The ALBI score was calculated from serum albumin and bilirubin using the following formula from a previous report: 5) ALBI score = (log10 bilirubin [µmol/L] × 0.66) + (albumin [g/L] × − 0.085) High and low ALBI score groups were defined using logistic regression analysis for 3-year overall survival (OS). Liver fibrosis was evaluated using the FIB-4 index, calculated as follows: 15) FIB-4 index = age (years) × AST [U/l]/(platelets [109/L] × (ALT [U/L])1/2) A FIB-4 cutoff value of 1.3 was used according to the same report. To assess cholesterol metabolism, we evaluated the LDL-C/HDL-C ratio, TC/HDL-C ratio, and Atherogenic Index of Plasma (log[TG/HDL-C]), all of which are associated with cardiovascular risk 16 - 18) . Study Endpoints The primary endpoint was OS rates in the high and low ALBI score groups. OS was also compared between groups after propensity score matching. Secondary endpoints included differences in cholesterol parameters among the groups, OS rates in the high and low FIB-4 index groups and OS stratified by LDL-C level or LDL-C/HDL-C ratio. Additionally, the impact of statin use on OS, ALBI score, FIB-4 index, and cholesterol profiles was evaluated. Statistical Analysis All statistical analyses were performed using JMP Pro version 17 (SAS institute Inc., Cary, NC, USA). Categorical variables are presented as numbers and percentages and continuous variables as means with standard error and 95% confidence intervals in parentheses. OS was estimated using the Kaplan–Meier method, and survival curves were compared with the log-rank test. Univariate and multivariate analyses of mortality risk were performed using the Cox proportional hazards model. Because HDL-C and LDL-C were not measured in all patients, subgroup analyses for OS and the mortality risk analyses involving these lipid parameters were restricted to those with available LDL-C data (n = 241, complete-case analysis). A two-sided P-value <0.05 was considered statistically significant. For pairwise comparisons among the four groups, the Bonferroni method was applied, with the significance level for each comparison set at 0.05 divided by the number of comparisons (0.05/6=0.0083); p values below 0.0083 were regarded as statistically significant. Propensity score matching was employed to balance covariates between high and low ALBI groups. Propensity scores were estimated using logistic regression, and nearest-neighbor matching without replacement created 1:1 matched pairs within a caliper of 0.2 standard deviations of the logit of the propensity score. Balance between groups was assessed using standardized mean differences. Covariates included in the matching model were age, sex, body mass index, ambulatory status, serum C-reactive protein (CRP) level, coronary artery disease, heart failure, end-stage renal disease, antithrombotic therapy, treatment type, and Rutherford classification. An absolute standardized difference <0.1 was considered ideal, and values <0.2 were deemed acceptable for indicating adequate balance across covariates. Because the distribution of CRP level was markedly right-skewed, we applied a logarithmic transformation and analyzed CRP as log (CRP [mg/dL] + 0.1). Results Patient Characteristics in High and Low ALBI Score Groups To classify CLTI patients into high and low ALBI score groups, we determined the optimal cutoff for 3-year OS using the receiver operating characteristic (ROC) analysis ( Supplementary Fig.1 ) . The optimal cutoff was −2.36 (area under the curve = 0.63, sensitivity = 67%, specificity = 57%), resulting in a high ALBI score group (≥ −2.36, n = 135) and a low ALBI score group (<−2.36, n = 128). Receiver operating characteristic (ROC) curve analysis for 3-year overall survival As shown in Table 1 , patients in the high ALBI score group were older (80 vs. 72 years, P<0.01), included fewer males (55% vs.71%, P<0.01), had lower BMI (19.4 kg/m2 vs. 22.0 kg/m2, P<0.01), and had a higher prevalence of bed-ridden status (44% vs. 2%, P<0.01). Regarding comorbidities, the high ALBI score group had lower prevalence of dyslipidemia, coronary artery disease, and end-stage renal disease but a higher prevalence of heart failure (25% vs. 8%, P<0.01). Only four patients in each group had a history of liver disease (controlled hepatitis). In terms of limb conditions and treatment, the high ALBI score group included more Rutherford stage 6 patients and underwent more amputations and endovascular procedures. Patients in this group were also less likely to receive antithrombotic therapy. Table 1.Patient baseline characteristicsVariables All (n = 263) Low ALBI score group (n = 128) High ALBI score group (n = 135) P Age76±1 (75–77)72±1 (71–74)80±1 (79–82)<0.01Sex (male)165 (63)91 (71)74 (55)<0.01 Body mass index (kg/m2) 20.7±0.2 (20.2–21.1)22.0±0.3 (21.4–22.6)19.4±0.3 (18.8–20.0)<0.01Ambulatory status<0.01Independent116 (44)85 (66)31 (23)Assisted/wheelchair84 (32)40 (31)44 (33)Bed-ridden63 (24)3 (2)60 (44)Smoking<0.01Current12 (5)5 (4)7 (5)Past65 (25)43 (34)22 (16)Never186 (71)80 (63)106 (79)Hypertension188 (71)98 (77)90 (67)0.07Diabetes mellitus171 (65)95 (74)76 (56)<0.01Dyslipidemia92 (35)64 (50)28 (21)<0.01Coronary artery disease126 (48)73 (57)53 (39)<0.01Heart failure44 (17)10 (8)34 (25)<0.01Cerebrovascular disease142 (54)62 (48)80 (59)0.08End-stage renal disease108 (41)64 (50)44 (33)<0.01Chronic liver disease8 (3)4 (3)4 (3)1.00Limbs and treatmentsPreprocedural ABI0.59±0.03 (0.54–0.65)0.58±0.03 (0.51–0.65)0.63±0.05 (0.52–0.73)0.43Rutherford<0.015188 (71)188 (71)188 (71)675 (29)75 (29)75 (29)Initial treatment<0.01Major amputation85 (32)13 (10)72 (53)Revascularization178 (68)115 (90)63 (47)Revascularization procedures<0.01Bypass48 (18)48 (18)48 (18)Endovascular therapy130 (49)130 (49)130 (49)Antithrombotic therapy206 (78)109 (85)97 (72)0.01Statin use56 (21)33 (26)23 (17)0.10Laboratory dataALBI score−2.27±0.04 (−2.34–−2.19)−2.77±0.04 (−2.83–−2.71)−1.80±0.03 (−1.86–1.74)<0.01FIB-4 index2.36±0.16 (2.05–2.70)1.78±0.22 (1.34–2.21)2.91±0.21 (2.49–3.34)<0.01White blood cell count (/μL)8400±270 (7860–8940)7140±380 (6400–7880)9600±370 (8870–10320)<0.01Hemoglobin (mg/dL)11.0±0.1 (10.8–11.2)11.7±0.2 (11.4–12.0)10.3±0.1 (10.0–10.6)<0.01 Platelet count (103/μL) 26.2±1.5 (23.1–29.2)23.5±2.2 (19.2–27.9)28.7±2.1 (24.5–32.9)0.10PT-INR1.40±0.06 (1.28–1.53)1.38±0.09 (1.20–1.56)1.43±0.09 (1.25–1.60)0.73APTT (sec)35.8±0.8 (34.3–37.4)34.3±1.1 (32.1–36.6)37.2±1.1 (35.1–39.3)0.07Albumin (g/dL)3.31±0.04 (3.22–3.39)3.88±0.04 (3.80–3.94)2.77±0.04 (2.70–2.84)<0.01Total bilirubin (mg/dL)0.43±0.01 (0.40–0.46)0.40±0.02 (0.36–0.44)0.46±0.02 (0.42–0.50)0.03Aspartate aminotransferase (U/L)23.3±1.2 (21.0–25.6)19.8±1.7 (16.6–23.1)26.6±1.6 (23.4–29.7)<0.01Alanine aminotransferase (U/L)17.2±1.0 (15.2–19.2)17.1±1.5 (14.2–19.9)17.4±1.4 (14.6–20.2)0.87HbA1c (%)6.4±0.1 (6.2–6.6)6.5±0.1 (6.2–6.8)6.2±0.1 (6.0–6.5)0.15C-reactive protein (mg/dL)3.9±0.3 (3.2–4.6)1.6±0.4 (0.7–2.5)6.1±0.4 (5.2–6.9)<0.01 eGFR (mL/min/1.73m2) 38±3 (32–43)30±4 (22–39)43±4 (22–39)0.02Triglyceride (mg/dL) 110±5 (100–119) [n = 244] 125±7 (112–138) [n = 124] 94±7 (81–107) [n = 120] <0.01 TC (mg/dL)* 160±3 (155–166) [n = 244] 173±4 (166–180) [n = 124] 147±4 (140–155) [n = 120] <0.01 LDL-C (mg/dL)* 95±3 (91–100) [n = 241] 100±3 (94–106) [n = 121] 90±3 (84–97) [n = 120] <0.01 HDL-C (mg/dL)* 43±1 (41–45) [n = 243] 48±1 (45–51) [n = 124] 39±1 (36–41) [n = 119] <0.01 RLP-C (mg/dL)* 5.36±0.51 (4.34–6.37) [n = 150] 4.26±0.72 (2.83–5.69) [n = 76] 6.42±0.71 (5.01–7.83) [n = 74] 0.03 LDL-C/HDL-C ratio* 2.38±0.07 (2.25–2.52) [n = 240] 2.20±0.10 (2.01–2.38) [n = 121] 2.57±0.10 (2.38–2.76) [n = 119] <0.01 TC/HDL-C ratio* 4.00±0.09 (3.82–4.17) [n = 241] 3.80±0.12 (3.56–4.04) [n = 123] 4.18±0.13 (3.94–4.43) [n = 118] 0.03 Atherogenic Index of Plasma* 0.36±0.02 (0.33–0.40) [n = 243] 0.35±0.03 (0.30–0.40) [n = 124] 0.37±0.03 (0.32–0.42) [n = 119] 0.61ABI, ankle–brachial index; ALBI, Albumin–Bilirubin score; FIB-4, fibrosis-4 index; PT-INR, prothrombin time–international normalized ratio; APTT, Activated partial thromboplastin time; eGFR, estimated glomerular filtration rate; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; RLP-C, remnant-like particle cholesterol.*Patient numbers are shown in brackets. Patient baseline characteristics All (n = 263) ABI, ankle–brachial index; ALBI, Albumin–Bilirubin score; FIB-4, fibrosis-4 index; PT-INR, prothrombin time–international normalized ratio; APTT, Activated partial thromboplastin time; eGFR, estimated glomerular filtration rate; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; RLP-C, remnant-like particle cholesterol. *Patient numbers are shown in brackets. ALBI Score, FIB-4 Index, and Laboratory Data among Groups In all patients, the mean ALBI score was −2.27±0.04 (−2.34 to −2.19) and the mean FIB-4 index was 2.36±0.16 (2.05–2.70). Correlation analysis demonstrated a weak but statistically significant linear relationship between ALBI score and FIB-4 index (R = 0.31, P<0.01). Consistent with this finding, the high ALBI score group had a significantly higher FIB-4 index ( Table 1 ) . Regarding laboratory data, patients in the high ALBI score group lower serum albumin and higher total bilirubin levels. They also exhibited white blood cell counts and C-reactive protein levels. Lipid profiles showed that the high ALBI score group had lower TC, HDL-C and LDL-C levels. In contrast, the RLP-C level, the LDL-C/HDL-C and TC/HDL-C ratios were significantly higher in the high ALBI score group compared with the low ALBI score group. There were no significant differences in the Atherogenic Index of Plasma between groups. The 22 patients without LDL measurements had a mean age of 77 years, among whom 8 underwent major amputation and 14 underwent revascularization, with 15 classified into the high ALBI score group (11%) and 7 into the low ALBI score group (5%). ALBI Score, FIB-4 Index, and OS The high ALBI score group had significantly lower OS compared with the low ALBI score group ( Fig.1a ) . The 3-year OS rates for all patients, and for the high and low ALBI score groups, were 48±4%, 36%±6%, and 57%±5%, respectively. After propensity matching, 54 patients were included in each group ( Table 2 , Fig.1b ) . After propensity score matching, liver disease remained inadequately balanced (SD = 0.27), whereas all other covariates achieved acceptable balance with standardized mean differences <0.20. The adjusted high ALBI score group continued to show lower 3-year OS than the adjusted low ALBI score group (43±9% vs. 55%±8%, P = 0.04). Similarly, patients with a high FIB-4 index (≥ 1.3) demonstrated poorer survival than those with a low FIB-4 index (3-year OS, 40%±5% vs. 73 %±6%, P<0.01, Fig.1c ). Regarding causes of death, cerebrocardiovascular diseases and infections were the most frequent in both groups, and no significant differences were observed between the groups ( Table 3 ) . Three-year overall survival rates: (a) high vs. low ALBI score groups; (b) propensity score-matched high vs. low ALBI score groups; (c) high vs. low FIB-4 index groups; (d) high vs. low ALBI score groups stratified by low LDL-C (<100 mg/dL) vs. high LDL-C (≥ 100mg/dL); (e) high vs. low FIB-4 index groups stratified by low LDL-C (<100 mg/dL) vs. high LDL-C (≥ 100mg/dL); (f) high vs. low ALBI score groups stratified by low LDL-C/HDL-C ratio (<2.5) vs. high LDL-C/HDL-C ratio (≥ 2.5); (g) high vs. low FIB-4 index groups stratified by low LDL-C/HDL-C ratio (<2.5) vs. high LDL-C/HDL-C ratio (≥ 2.5) Asterisks indicate comparisons showing statistically significant differences among the four groups (P<0.0083). Table 2.Baseline characteristics of patients after propensity score matching between high and low ALBI score groupsVariables Low ALBI score group (n = 54) High ALBI score group (n = 54) P SDAge77±1 (75–80)77±1 (75–79)0.770.06Sex (male)35 (65)39 (72)0.530.16Body mass index20.6±0.5 (19.7–21.5)20.4±0.4 (19.6–21.3)0.760.06Ambulatory status50 (93)51 (94)1.000.08Hypertension40 (74)37 (69)0.670.12Diabetes mellitus35 (65)38 (70)0.680.12Dyslipidemia18 (33)14 (26)0.530.16Coronary artery disease29 (54)32 (59)0.700.11Heart failure8 (15)9 (17)1.000.06Cerebrovascular disease28 (52)29 (54)1.000.04End-stage renal disease19 (35)21 (39)0.840.08Chronic liver disease4 (7)1 (2)0.360.27Rutherford 611 (20)11 (20)1.000.0Major amputation10 (19)12 (22)1.000.09Antithrombotic therapy44 (81)45 (83)1.000.05Statin use16 (30)14 (26)0.830.08CRP (mg/dL)3.06±0.6 (1.93–4.19)2.52±0.4 (1.77–3.26)0.420.16SD, Standardized difference. Baseline characteristics of patients after propensity score matching between high and low ALBI score groups SD, Standardized difference. Table 3.Causes of death in high and low ALBI score groupsVariables All (n = 119) Low ALBI score group (n = 52) High ALBI score group (n = 67) P Cerebrocardiovascular diseases33 (28)18 (35)15 (22)0.37Infections37 (31)18 (35)19 (28)Organ failure24 (20)8 (15)16 (24)Malignancy6 (5)2 (4)4 (6)Others19 (16)6 (11)13 (19) Causes of death in high and low ALBI score groups All (n = 119) Given that a high ALBI score and a high FIB-4 index were associated with lower cholesterol levels and poorer survival, we subsequently evaluated OS stratified by LDL-C level and LDL-C/HDL-C ratio ( Figs.1d-g ) . Among patients with a high ALBI score, those with low LDL-C (<100 mg/dL) had lower 3-year OS than those with high LDL-C (≥ 100 mg/dL), although this difference was not statistically significant (25%±7% vs. 39%±11%, P = 0.1805; Fig.1d ). Conversely, a high ALBI score was associated with reduced OS even among patients with high LDL-C (39%±11% vs. 76%±6%, P<0.0001; Fig.1d ). Then, among patients with a high FIB-4 index, those with low LDL-C exhibited significantly lower 3-year OS than those with high LDL-C (31%±6% vs. 55%±7%, P = 0.0079; Fig.1e ). Furthermore, among patients with low LDL-C, a high FIB-4 index was associated with reduced OS compared with a low FIB-4 index (31%±6% vs. 73%±8%, P = 0.0005; Fig.1e ). In contrast, the effect of the LDL-C/HDL-C ratio on OS was not clearly demonstrated, whereas a high ALBI score and a high FIB-4 index remained significantly associated with poorer prognosis, irrespective of the LDL-C/HDL-C ratio ( Figs.1f, g ) . Prognostic Factors for 3-Year OS Univariate analysis identified age ≥ 75 years, low BMI (<18.5 kg/m2), non-ambulatory status, Rutherford stage 6, major amputation, heart failure, high ALBI score (≥ −2.36), and high FIB-4 index (≥ 1.3), CRP elevation (≥ 1.0 mg/dL), and low LDL-C (<100 mg/dL) as adverse prognostic factors for 3-year OS, whereas statin use was associated with improved survival ( Table 4 ) . Table 4.Cox proportional hazards model for 3-year overall survivalVariablesUnivariateMultivariateHR95% CIP AHR95% CIP Age ≥ 75 years2.361.523.64<0.011.390.842.300.21Female sex1.030.671.580.90 Low body mass index (<18.5 kg/m2) 2.751.834.12<0.011.611.002.610.05Nonambulatory status3.672.385.67<0.011.510.902.540.12Rutherford 6 vs. Rutherford 52.051.333.15<0.011.020.581.770.96Amputation vs. revascularization2.871.914.29<0.011.220.682.170.50Statin use0.520.300.920.020.670.361.250.21End-stage renal disease1.060.711.580.78Heart failure2.771.714.47<0.012.301.353.91<0.01High ALBI score (≥ −2.36)3.942.576.04<0.011.961.123.430.02High FIB-4 index (≥ 1.3)2.641.564.47<0.012.351.34.24<0.01CRP elevation (≥ 1.0 mg/dL)1.791.182.71<0.011.20.741.930.46Low LDL-C (<100 mg/dL)1.961.263.06<0.011.821.122.970.02High LDL-C/HDL-C ratio (≥ 2.5)0.970.611.540.90HR, hazard ratio; CI confidential interval; AHR, adjusted hazard ratio Cox proportional hazards model for 3-year overall survival HR, hazard ratio; CI confidential interval; AHR, adjusted hazard ratio Multivariate analysis revealed that low BMI (<18.5), heart failure, high ALBI score (≥ −2.36), high FIB-4 index (≥ 1.3), and low LDL-C (<100 mg/dL) were independent predictors of poor OS. Statin Use and ALBI Score, FIB-4 Index, and Cholesterol Profiles Finally, we assessed the impact of statin therapy, which inhibits hepatic HMG-CoA reductase, on OS, liver function, and cholesterol profiles ( Table 5 ) . Statin use was associated with improved OS; the 3-year OS rates were 68%±7% for patients on statins versus 46%±4% for those not on statins ( Fig.2 ) . Patients receiving statins had lower ALBI scores compared with those not receiving statins (−2.43 vs. −2.23, P = 0.03), suggesting better liver function. In contrast, most cholesterol parameters did not differ significantly between the groups, except for the Atherogenic Index of Plasma. Table 5.Characteristics and laboratory parameters of patients stratified by statin useVariables Statin (+) (n = 56) Statin (−) (n = 207) P ALBI score−2.43±0.08 (−2.58–−2.27)−2.23±0.04 (−2.31–−2.15)0.03FIB-4 index1.88±0.34 (1.21–2.55)2.49±0.18 (2.14–2.84)0.11Triglyceride (mg/dL)137±10 (118–157)102±5 (91–112)<0.01TC (mg/dL) 160±6 (149–172) [n = 54] 160±3 (154–166) [n = 190] 0.93LDL-C (mg/dL) 92±5 (82–101) [n = 52] 97±3 (92–102) [n = 189] 0.36HDL-C (mg/dL) 44±2 (40–48) [n = 54] 43±1 (41–46) [n = 189] 0.78RLP -C (mg/dL) 6.47±4.46 (4.34–8.48) [n = 38] 4.98±0.59 (3.81–6.15) [n = 112] 0.20LDL-C/HDL-C ratio 2.17±0.14 (1.88–2.45) [n = 52] 2.46±0.08 (2.31–2.61) [n = 188] 0.08TC/HDL-C ratio 3.84±0.19 (3.47–4.20) [n = 54] 4.03±0.10 (3.84–4.23)[n = 187] 0.35Atherogenic Index of Plasma 0.44±0.04 (0.36–0.52) [n = 54] 0.34±0.02 (0.30–0.38) [n = 189] 0.03 Characteristics and laboratory parameters of patients stratified by statin use Three-year overall survival rates of patients with and without statin therapy Discussion In this study, we demonstrated that a high ALBI score in CLTI patients was associated with a higher FIB-4 index, lower levels of most cholesterol fractions, an elevated LDL-C/HDL-C ratio, and poorer survival. These findings suggests that liver dysfunction, potentially via impaired cholesterol metabolism, may be a significant risk factor for survival in CLTI patients. The ALBI score was originally categorized into three grades using cutoffs of −2.60 and −1.39 7) . In our cohort of patients with CLTI, the optimal ALBI cutoff value for predicting adverse survival outcomes was −2.36, which lies between the conventional thresholds for ALBI grade 1 and grade 2. This finding suggests that even mild impairment of liver function, as captured by a modestly elevated ALBI score, may have a clinically relevant impact on prognosis in patients with CLTI. The correlation between ALBI score and FIB-4 index is particularly noteworthy, as these indices are derived from entirely different parameters. The observed association implies the presence of subclinical liver fibrosis in patients with CLTI. Furthermore, patients with high ALBI scores had more systemic comorbidities and lower plasma cholesterol levels compared with those with low ALBI scores ( Table 1 ) . While decreased serum cholesterol is a recognized marker of malnutrition 19) , it may also reflect impaired hepatic function, since approximately 70%–80% of cholesterol in the human body is produced endogenously, with only 20%–30% derived from dietary intake. Therefore, high ALBI scores accompanied by low cholesterol levels in CLTI patients may result not only from malnutrition but also from reduced hepatic cholesterol biosynthesis due to liver dysfunction. Beyond altered lipid synthesis, hepatic dysfunction may contribute to adverse vascular outcomes through multiple pathophysiologic pathways. Impaired hepatic clearance of inflammatory cytokines and endotoxins can promote chronic low-grade inflammation, enhancing oxidative stress and endothelial dysfunction—both key drivers of atherosclerosis progression and microvascular failure 20) . Liver dysfunction also affects lipoprotein remodeling, leading to decreased HDL antioxidant capacity and enrichment of small dense LDL, which together accelerate plaque formation and vascular injury 21 , 22) . Moreover, reduced albumin synthesis may further impair endothelial protection and nitric oxide bioavailability 23 , 24) . These mechanisms collectively create a proatherogenic and proinflammatory milieu that may exacerbate tissue ischemia and delay wound healing in CLTI. We also observed that not only high ALBI scores but also low LDL-C level was associated with poorer OS ( Table 4 ) . Although lowering LDL-C is a primary targets for preventing atherosclerosis progression, the phenomenon of the “cholesterol paradox”—a paradoxical association between low LDL-C levels and poor prognosis in patients with cardiac diseases—has been previously reported 25 - 29) . Accordingly, the poor OS observed in patients with low LDL-C in our study is consistent with these reports, especially given the association of high ALBI scores with low LDL-C and the high prevalence of coronary artery disease and heart failure in this cohort. In our cohort, the high ALBI group had a lower prevalence of diagnosed dyslipidemia and fewer patients receiving statins yet showed lower LDL-C levels than the low ALBI group. This pattern indicates that low LDL-C in the high ALBI group is more likely to arise from metabolic deterioration related to liver dysfunction and/or malnutrition, rather than from intensive lipid-lowering therapy. Furthermore, although the LDL-C/HDL-C ratio was elevated in the high ALBI group, both LDL-C and HDL-C levels were lower in this group than in the low ALBI group ( Table 1 ) . Given that the high ALBI group also exhibited higher white blood cell counts and elevated CRP levels, a possible explanation is that chronic inflammatory conditions are frequently associated with a characteristic alteration in lipid profiles, in which total cholesterol decreases but HDL cholesterol declines more prominently, leading to a relatively higher LDL/HDL ratio even when absolute LDL levels are not substantially elevated 30) . These findings suggest that high ALBI scores are linked to reductions in all major cholesterol fractions and that low absolute cholesterol levels, rather than elevated LDL-C/HDL-C ratios, are stronger predictors of poor OS. An elevated ALBI score may therefore reflect a diminished TC reserve, indicating a limited capacity of the body to maintain essential lipid levels in the presence of systemic inflammation. Finally, we examined the influence of statin therapy on liver function, cholesterol parameters, and OS in CLTI patients. Notably, statin use was associated with both improved OS and lower ALBI scores in this cohort ( Table 5 ) . The Global Vascular Guidelines recommend stains as a key component of optimal medical therapy for all PAD patients undergoing lower extremity revascularization, and statin therapy is known to reduce all-cause and cardiovascular mortality in patients with CLTI. In addition to lipid-lowering effects, these benefits may partly be mediated through statin-induced improvement of hepatic function 26 - 28) . Previous studies have reported that statins can reduce systemic and hepatic inflammation, protect endothelial function, support angiogenesis, and improve portal hypertension and liver fibrosis 31 - 33) . Therefore, the improved survival and lower ALBI scores observed in statin-treated patients in our study may reflect these pleiotropic effects in addition to cholesterol reduction. This study has several limitations. First, it was a retrospective, single-center study with a relatively small sample size, which may introduce selection bias and limit the statistical power to identify additional risk factors. For instance, several lipid parameters were only available in subsets of patients, and lipid-related analyses were conducted using complete cases. This may have reduced statistical power and could have introduced selection bias if missingness was not completely random. Second, liver function assessment relied solely on the ALBI score and was not corroborated by other clinical evaluations, such as imaging studies (e.g., ultrasonography or computed tomography) or alternative serological markers (e.g., cholinesterase). Third, statin dosing and response may differ between Japan and other countries due to variations in genetic sensitivity, metabolism, and treatment guidelines.Further studies are warranted to elucidate the relationship between CLTI and liver function. Such investigations may also inform the development of novel therapeutic agents that, like statins, provide benefits beyond lipid lowering. Conclusion Liver dysfunction, as indicated by a high ALBI score, is associated with liver fibrosis, lower serum cholesterol levels with a higher LDL-C/HDL-C ratio, and poorer survival in patients with CLTI. Conflicts of Interest The authors declare no conflict of interest. Declaration of Generative AI in ScientificWriting During the preparation of this manuscript, the authors used Perplexity Pro® for academic English proofreading. Acknowledgements In order to improve the quality of the English in this manuscript, professional editing was carried out by Enago (https://www.enago.jp/). Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Author Contributions Study conception: KI Data collection: All authors Analysis: KI Investigation: All authors Writing: KI Critical review and revision: All authors Final approval of the article: All authors Accountability for all aspects of the work: All authors